Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235484 | 0.83 | ALPL (0.46) | RAB9ANPC1ALPLPIK3C3HCAR3 | |
| SCHEMBL28518683 | 0.81 | HCAR3 (0.57) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL14235819 | 0.79 | HCAR3 (0.51) | ALPLHCAR3MMEHCAR2 | |
| SCHEMBL23854654 | 0.78 | MAPK1 (0.59) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL4420465 | 0.77 | RAB9A (0.57) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL15318182 | 0.73 | RAB9A (0.53) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL3498417 | 0.73 | CCNA2 (0.60) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL2629289 | 0.73 | ALPL (0.49) | RAB9ANPC1ALPLHCAR3MME | |
| SCHEMBL15318183 | 0.72 | RAB9A (0.51) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL15318181 | 0.72 | RAB9A (0.51) | RAB9ANPC1NR1I2AHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | RAB9A 4343/4885NPC1 2552/4885NR1I2 716/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | RAB9A 2748/4885NPC1 2838/4885NR1I2 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.